Analyst Expectations for Kymera Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target among 4 analysts is $32.25, with a high of $38.00 and a low of $24.00. This target suggests a significant 41.1% decrease from the previous target of $54.75. Analysts rate stocks based on future earnings potential and company updates.
November 13, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kymera Therapeutics has a new average analyst price target of $32.25, indicating a potential downside from the previous target, with mixed analyst ratings.
The new average price target represents a significant decrease from the previous target, which could lead to negative investor sentiment and a potential decrease in KYMR's stock price in the short term. The mixed analyst ratings further contribute to the uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100